Trellus Health Shares Surge Over 100% on J&J Contract Extension

Shares of Trellus Health PLC (TRLS) more than doubled in early trading following the announcement of a strategic contract extension with Johnson & Johnson Health Care Systems. The agreement extends the current partnership by an additional six months, securing the collaboration until mid-2026. Under the terms, Trellus Health will continue to provide its Trellus Elevate program to patients suffering from inflammatory bowel disease (IBD) who are prescribed J&J therapies. The extension maintains the existing economic structure, including a fixed monthly fee, providing the company with significant revenue continuity. Market analysts view this renewal as a strong validation of Trellus’s digital health platform by a global healthcare giant. The massive price jump highlights the sensitivity of small-cap AIM-listed stocks to successful partnerships and contract renewals with major industry players.